TENEOBIO

teneobio-logo

TeneoBio is a biotechnology company that specializes in the development of human heavy chain antibodies. It has several products in pre-clinical and clinical development for the treatment of multiple myeloma, prostate cancer, and immune disorders. TeneoBio’s antibody discovery engine is based on UniRat™, a proprietary heavy chain only, human immunoglobulin transgenic rat.

#SimilarOrganizations #People #Financial #Website #More

TENEOBIO

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2009-01-01

Address:
Newark, California, United States

Country:
United States

Website Url:
http://www.teneobio.com

Total Employee:
1+

Status:
Active

Contact:
650-899-8200

Technology used in webpage:
Domain Not Resolving SPF Amazon Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Amazon Route 53 AWS Global Accelerator MediaElement.js Amazon Oregon Region


Similar Organizations

arrowhead-pharmaceuticals-logo

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.

aura-biosciences-logo

Aura Biosciences

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

epivax-logo

EpiVax

EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.

imvax-logo

Imvax

Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.

solvanix-logo

Solvanix

Solvanix is a biotechnology company that improves stability and reducing the aggregation of fully human antibodies.


Current Advisors List

jeff-bird_image

Jeff Bird Investor & Board Member @ TeneoBio
Board_member
2017-01-01

Current Employees Featured

roland-buelow_image

Roland Buelow
Roland Buelow CEO @ TeneoBio
CEO
2009-08-01

nathan-trinklein_image

Nathan Trinklein
Nathan Trinklein Chief Technology Officer @ TeneoBio
Chief Technology Officer
2015-07-01

Founder


roland-buelow_image

Roland Buelow

Investors List

lightspeed-venture-partners_image

Lightspeed Venture Partners

Lightspeed Venture Partners investment in Venture Round - TeneoBio

sutter-hill-ventures_image

Sutter Hill Ventures

Sutter Hill Ventures investment in Venture Round - TeneoBio

Official Site Inspections

http://www.teneobio.com Semrush global rank: 8.49 M Semrush visits lastest month: 523

  • Host name: a4ec4c6ea1c92e2e6.awsglobalaccelerator.com
  • IP address: 15.197.142.173
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "TeneoBio"

TeneoBio - Crunchbase Company Profile & Funding

TeneoBio is a biotechnology company that specializes in the development of human heavy chain antibodies. It has several products in pre-clinical and …See details»

Teneobio - Amgen

Amgen’s Acquisition of Teneobio is Now Complete. Learn More.See details»

Amgen To Acquire Privately Held Teneobio For $900 Million In …

Jul 27, 2021 THOUSAND OAKS, Calif. and NEWARK, Calif., July 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen …See details»

Amgen Successfully Completes Acquisition Of Teneobio, Inc.

THOUSAND OAKS, Calif., Oct. 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of …See details»

Amgen Successfully Completes Acquisition Of Teneobio, Inc. - PR …

Effective as of Oct. 19, 2021, Amgen has acquired all outstanding equity of Teneobio in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments, to …See details»

Teneobio, Inc. Company Profile | Newark, CA - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Teneobio, Inc. of Newark, CA. Get the latest business insights from Dun & Bradstreet.See details»

Press Release Distribution and Management - GlobeNewswire

NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic …See details»

TeneoBio 2025 Company Profile: Valuation, Investors ... - PitchBook

TeneoBio has raised $13.5M. Who are TeneoBio’s investors? Lightspeed Venture Partners and Tesaro have invested in TeneoBio. Who are TeneoBio’s competitors? Linnaeus Therapeutics …See details»

TeneoBio Company Profile - Office Locations, Competitors ... - Craft

TeneoBio is a biotechnology company developing biologics such as human heavy chain antibodies (UniAbs) as therapeutics against cancer, autoimmunity, and infectious diseases. It …See details»

$2.5B Teneobio Deal Complements Amgen’s Core and …

Jul 28, 2021 Michael Vi / Shutterstock. Amgen is snapping up privately-held TeneoBio and its class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.. Through the acquisition, which includes a …See details»

Amgen finalizes Teneobio acquisition - Drug Discovery …

Oct 19, 2021 Before the acquisition, Teneobio distributed some assets to its equity holders related to three affiliates dubbed “TeneoTwo,” “TeneoFour” and “TeneoTen.” Among the included assets were TNB-486, anti-CD38 antibodies …See details»

Gilead-partnered Teneobio and its next-gen cancer work snapped …

Jul 28, 2021 “The Teneobio team is enthusiastic about joining forces with Amgen, a pioneer of biotherapeutics. Amgen's R&D resources and its extensive clinical experience in immuno …See details»

Teneobio falls short of Amgen’s expectations - ApexOnco

Oct 31, 2023 Amgen had bought Teneobio, a subsidiary of a private business focusing on heavy chain-only antibodies, for $993m up front, and AMG 340, a T-cell engager against PSMA that …See details»

Teneobio Acquisition Adds Talent and New Types of Antibodies to …

Jan 14, 2022 Teneobio has engineered a T cell engager that binds with a very low affinity to the CD3 receptor on T cells. Both high- and low-affinity T cell binders are needed in cancer …See details»

Kite Licenses Antibodies and Establishes Collaboration With …

Apr 2, 2020 SANTA MONICA, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a …See details»

Amgen stops cancer trial, taking $650M BiTE out of earnings

Oct 31, 2023 Amgen’s Teneobio misadventure has taken a $650 million BiTE out of its earnings. The Big Biotech took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in …See details»

Etentamig - Drug Targets, Indications, Patents - Synapse - Patsnap

Mar 10, 2025 Etentamig: a BCMA inhibitors, CD3 stimulants Drug, Initially developed by TeneoBio, Inc., Now, its global highest R&D status is Phase 3, Mechanism: BCMA inhibitors(B …See details»

Potential Myeloma Treatment, TNB-383B, Makes Progress in New …

Feb 20, 2019 Teneobio has already filed an investigational new drug application with the U.S. Food and Drug Administration in January 2019 to begin clinical testing of TNB-383B as …See details»

Multi-specific therapeutic antibodies - FreeMind Group

Page 3 Teneobio Overview Proprietary transgenic rats for human antibody discovery UniRat and Omniflic High throughput sequence-based human antibody discovery engine Next-gen …See details»

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody …

3 Teneobio, Inc, Newark, California, USA [email protected]. PMID: 34088740 PMCID: PMC8183203 DOI: 10.1136/jitc-2021-002488 Abstract Background: Therapeutic options …See details»

linkstock.net © 2022. All rights reserved